{"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] . The following adverse reactions have been identified during post-approval use of IC-GREEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders: Anaphylaxis, urticaria The most common adverse reactions reported are anaphylaxis and urticaria. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Diagnostic Green LLC at 1-844-424-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed to evaluate the potential for carcinogenicity, mutagenicity, or impairment of fertility by indocyanine green."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor. These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and macro-vasculature, blood flow and tissue perfusion, the extrahepatic biliary ducts, and for lymphatic mapping of lymph nodes and lymphatic vessels. 12.2 Pharmacodynamics There are no pharmacodynamic data. 12.3 Pharmacokinetics Distribution Following intravenous injection, indocyanine green binds to plasma proteins (98%) and is largely confined to the intravascular compartment. Indocyanine green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin. Following interstitial injection, indocyanine green binds to proteins in lymph fluid and the interstitial space, is taken up by the lymphatic vessels, and drains to the lymph nodes. Since excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature, IC-GREEN is useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera. Elimination Indocyanine green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Lymphatic Mapping of Cervical and Uterine Cancer The effectiveness of IC-GREEN for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer has been established based on a study of another formulation of indocyanine green for injection. Below is a description of the FILM Study (NCT 02209532). The study was a randomized, prospective, multi-center, open-label study in patients with early stage uterine or cervical cancer and no known regional nodal or metastatic disease by standard clinical evaluation. Indocyanine green and a blue dye comparator were injected into the cervix of patients at the beginning of the operative procedure. A total of 176 patients were randomized to receive either indocyanine green followed by blue dye or blue dye followed by indocyanine green. A total of four 1 mL injections of a 1.25 mg/mL solution of indocyanine green for a total dose of 5 mg were administered interstitially into the cervix at the 3 o'clock and 9 o'clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position. Lymphatic mapping was performed intraoperatively using a fluorescence imaging device and standard light, followed by excision of tissues identified by indocyanine green, blue dye, or the surgeon's visual and palpation examination. The resected tissues were evaluated by histopathology to confirm presence of lymph nodes. The efficacy of indocyanine green in the detection of lymphatic vessels and lymph nodes during lymphatic mapping procedures was determined by the number of histology-confirmed lymph nodes detected by indocyanine green and/or the blue dye comparator. The mean age of the 176 patients was 63 years (range: 31 to 88 years); distribution by race and ethnicity was 79% White, 4% Black or African American, 3% Asian, 13% Hispanic/Latino and 1% other. Table 1 shows the distribution of resected, confirmed lymph nodes detected by indocyanine green or blue dye in the modified intent-to-treat population (mlTT). Among the confirmed lymph nodes identified, 93% were identified using indocyanine green, and 43% were identified using blue dye, a difference of 50% [95% confidence interval 39% to 60%]. Table 1: Distribution of Resected, Confirmed Lymph Nodes Detected by Indocyanine Green or Blue Dye (BD) Analysis Population Nodes (n) All Lymph Nodes Detected with Indocyanine Green All Lymph Nodes Detected with BD Lymph Nodes Detected with Indocyanine Green Only Lymph Nodes Detected with BD Only Lymph Nodes Detected with Neither mlTT 513 (476/513) 93% (220/513) 43% (262/513) 51% (6/513) 1% (31/513) 6% Table 2 shows the number of patients with at least one resected, confirmed lymph node and the number of patients with at least one bilateral lymph node pair detected by indocyanine green or blue dye. With indocyanine green, approximately 97% of patients had at least one resected, confirmed lymph node detected and 73% had at least one bilateral lymph node pair detected, compared with 68% and 28%, respectively, with blue dye (p-values for each analysis <0.0001). Table 2: Distribution of Patients with at Least One Confirmed Unilateral Lymph Node/ Bilateral Pair Detected by Indocyanine Green or Blue Dye (BD) *: patients with at least one resected confirmed lymph node detected unilaterally **: patients with at least one resected confirmed lymph node detected bilaterally Analysis Population Patients (n) Patients with All Lymph Nodes Detected with Indocyanine Green Patients with All Lymph Nodes Detected with BD Patients with Lymph Nodes Detected with Indocyanine Green only Patients with Lymph Nodes Detected with BD only Patients with Lymph Nodes Detected with Neither mlTT Unilateral* 172 (167/172) 97% (118/172) 68% (51/172) 30% (2/172) 1% (3/172) 3% mlTT Bilateral** (126/172) 73% (49/172) 28% (79/172) 46% (2/172) 1% (44/172) 26%"],"clinical_studies_table":["
Table 1: Distribution of Resected, Confirmed Lymph Nodes Detected by Indocyanine Green or Blue Dye (BD)
Analysis PopulationNodes (n)All Lymph Nodes Detected with Indocyanine GreenAll Lymph Nodes Detected with BDLymph Nodes Detected with Indocyanine Green OnlyLymph Nodes Detected with BD OnlyLymph Nodes Detected with Neither
mlTT513(476/513) 93%(220/513) 43%(262/513) 51%(6/513) 1%(31/513) 6%
","
Table 2: Distribution of Patients with at Least One Confirmed Unilateral Lymph Node/ Bilateral Pair Detected by Indocyanine Green or Blue Dye (BD)
*: patients with at least one resected confirmed lymph node detected unilaterally **: patients with at least one resected confirmed lymph node detected bilaterally
Analysis PopulationPatients (n)Patients with All Lymph Nodes Detected with Indocyanine GreenPatients with All Lymph Nodes Detected with BDPatients with Lymph Nodes Detected with Indocyanine Green onlyPatients with Lymph Nodes Detected with BD onlyPatients with Lymph Nodes Detected with Neither
mlTT Unilateral*172(167/172) 97%(118/172) 68%(51/172) 30%(2/172) 1%(3/172) 3%
mlTT Bilateral**(126/172) 73%(49/172) 28%(79/172) 46%(2/172) 1%(44/172) 26%
"],"contraindications":["4 CONTRAINDICATIONS IC-GREEN is contraindicated in patients with a history of hypersensitivity to indocyanine green. Reactions have included anaphylaxis [see Warnings and Precautions ( 5.1 )] . Hypersensitivity to indocyanine green ( 4 )"],"description":["11 DESCRIPTION IC-GREEN (indocyanine green for injection) is an optical imaging agent for intravenous or interstitial use. Each vial contains 10 mg or 25 mg of indocyanine green with not more than 5% sodium iodide as a sterile, lyophilized, green powder. IC-GREEN has a pH of 5.5-7.5 when reconstituted with Sterile Water for Injection, USP. The chemical name for Indocyanine Green is 1 H Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4- sulfobutyl)-2 H -benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt. Molecular Formula: C43H47N2NaO6S2; Molecular Mass: 774.96 g/mol, with the following structural formula: Indocyanine green has a peak spectral absorption at 805 nm in blood. Structural Formula"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Visualization of vessels, blood flow and tissue perfusion (2.5 mg/mL solution) o 1.25 mg to 5 mg by intravenous injection is recommended for a surgical procedure in adults and pediatric patients aged 1 month and older. o 3.75 mg to 10 mg by intravenous injection is recommended for visualization of perfusion in extremities through the skin for plastic, micro- and reconstructive surgeries in adults. o Additional doses may be administered. Do not exceed a total dose of 2 mg/kg. ( 2.1 ) • Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older (2.5 mg/mL solution) o 2.5 mg by intravenous injection at least 45 minutes prior to surgery. o Additional doses may be administered. Do not exceed a total dose of 2 mg/kg. ( 2.2 ) • Lymphatic mapping of cervical and uterine cancer in adults (1.25 mg/mL solution) o 5 mg interstitially as four 1 mL injections. o See Full Prescribing Information for injection techniques. ( 2.3 ) • Ophthalmic Angiography o Doses up to 40 mg in 2 mL of Sterile Water for Injection by intravenous injection. ( 2.4 ) • See Full Prescribing Information for reconstitution instructions. ( 2.5 ). 2.1 Recommended Dose, Administration and Imaging for Visualization of Vessels, Blood Flow and Tissue Perfusion Dosing Adults: The recommended dose of IC-GREEN for a single image sequence for visualization of vessels, blood flow and tissue perfusion in adults is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution. For visualization of perfusion in extremities through the skin in adults, the recommended dose is 3.75 mg to 10 mg administered intravenously as 1.5 mL to 4 mL of a 2.5 mg/mL solution. Immediately flush with a 10 mL bolus of 0.9% Sodium Chloride Injection. Pediatric patients aged 1 month and older: The recommended dose of IC-GREEN for a single image sequence for visualization of vessels, blood flow and tissue perfusion in pediatric patients aged 1 month and older is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution. Lower doses may be administered in younger patients and in those with lower body weight. Adjust the amount and type of flush to avoid volume and/or sodium overload. In both adults and pediatric patients aged 1 month and older, additional doses may be administered to obtain imaging sequences during the procedure. Do not exceed the maximum total dose of 2 mg/kg. Administration Prior to the imaging procedure, draw up the desired dose of IC-GREEN solution into appropriate syringes and prepare a 10 mL syringe of 0.9% Sodium Chloride Injection. Administer via a central or peripheral venous line using a three-way stopcock attached to an injection port on the infusion line. Inject the prepared IC-GREEN into the line as a tight bolus. Immediately switch the access on the stopcock and inject the prepared flush. Imaging Instructions IC-GREEN may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of vessels, blood flow and tissue perfusion. A fluorescence response should be visible in blood vessels within 5 seconds to 15 seconds after injection . 2.2 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary Ducts Dosing and Administration The recommended dose of IC-GREEN for visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older is 2.5 mg administered intravenously as 1 mL of a 2.5 mg/mL solution at least 45 minutes prior to surgery. Additional doses may be administered to obtain imaging sequences during the procedure. Do not exceed a total dose of 2 mg/kg. Imaging Instructions IC-GREEN may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of extrahepatic biliary ducts. Fluorescence is visible in the biliary tree within 45 minutes after injection. 2.3 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and Uterine Cancer Dosing and Administration The recommended dose of IC-GREEN for lymphatic mapping of cervical and uterine cancer in adults is 5 mg administered interstitially as four 1 mL injections of a 1.25 mg/mL solution into the cervix, at the 3 o’ clock and the 9 o’clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position. Imaging Instructions IC-GREEN may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping of cervical and uterine cancer. Fluorescent lymphatic vessels and lymph nodes should begin to be visible within 1 minute after injection . 2.4 Recommended Dose and Administration for Ophthalmic Angiography Dosing and Administration Doses up to 40 mg IC-GREEN in 2 mL of Sterile Water for Injection depending on the imaging equipment and technique used should be administered intravenously and immediately followed by a 5 mL bolus of 0.9% Sodium Chloride Injection. The antecubital vein can be used for IC-GREEN administration. 2.5 Reconstitution Instructions General • Prepare IC-GREEN using aseptic techniques prior to procedure. • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. • Inspect the reconstituted solution for particulate matter. The reconstituted solution should be a clear, green solution. • Use the prepared solution within 6 hours. • Discard any unused product. Visualization of Vessels, Blood Flow, Tissue Perfusion and Extrahepatic Biliary Ducts Dissolve 25 mg of IC-GREEN with 10 mL Sterile Water for Injection to form a concentration of 2.5 mg/mL indocyanine green. Dissolve 10 mg of IC-GREEN with 4.3 mL Sterile Water for Injection to form a concentration of 2.5 mg/mL indocyanine green. Lymphatic Mapping of Cervical and Uterine Cancer Dissolve 25 mg of IC-GREEN with 20 mL Sterile Water for Injection to form a concentration of 1.25 mg/mL indocyanine green. Dissolve 10 mg of IC-GREEN with 8.6 mL Sterile Water for Injection to form a concentration of 1.25 mg/mL indocyanine green. Ophthalmic Angiography Dissolve doses up to 40 mg of IC-GREEN with 2 mL Sterile Water for Injection."],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS For injection: 25 mg of indocyanine green as a sterile, lyophilized, green powder for reconstitution provided in a 25 mL single-patient-use vial. For injection: 10 mg of indocyanine green as a sterile, lyophilized, green powder for reconstitution provided in a 15 mL single-patient-use vial. For injection: 10 mg and 25 mg of indocyanine green as a lyophilized, green powder for reconstitution in a single-patient-use vial ( 3 )"],"drug_interactions":["7 DRUG INTERACTIONS Interference with Thyroid Radioactive Iodine Uptake Studies Because IC-GREEN contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of IC-GREEN. Interference with Thyroid Radioactive Iodine Uptake Studies: Do not perform radioactive iodine uptake studies for at least one week following the use of IC-GREEN. ( 7 )"],"effective_time":"20260130","geriatric_use":["8.5 Geriatric Use Of the total number of patients in clinical studies of indocyanine green for injection for visualization of vessels, blood flow and tissue perfusion, 7% were 65 and over, while 1% were 75 and over. Of the total number of patients in clinical studies of indocyanine green for injection for visualization of lymph nodes and lymphatic vessels during lymphatic mapping of cervical and uterine cancer, 9% were 65 and over, while 2% were 75 and over. Clinical studies of indocyanine green for injection for visualization of extrahepatic biliary ducts did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied 10 mg/vial: IC-GREEN (indocyanine green for injection) is supplied as a kit (NDC 70100-810-02) containing the following: • Six 15 mL single-patient-use vials of IC-GREEN (10 mg each) as a sterile, lyophilized green powder for reconstitution NDC 70100-710-01 • Six single-dose vials of Sterile Water for Injection (10 mL each) NDC 0409-4887-17 or NDC 0641-6147-10 25 mg/vial: IC-GREEN (indocyanine green for injection) is supplied as a kit (NDC 70100-825-02) containing the following: • Six 25 mL single-patient-use vials of IC-GREEN (25 mg each) as a sterile, lyophilized green powder for reconstitution NDC 70100-725-01 • Six single-dose vials of Sterile Water for Injection (10 mL each) NDC 63323-185-10 or NDC 0409-4887-17 or NDC 0641-6147-10 Storage and Handling Store at 20°C to 25°C (68°F to 77°F)."],"id":"bb82db71-b087-4274-bd9c-cb388d7dbaeb","indications_and_usage":["1 INDICATIONS AND USAGE • Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients aged 1 month and older ( 1.1 ) • Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older ( 1.2 ) • Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer ( 1.3 ) • Ophthalmic angiography in adults and pediatric patients ( 1.4 ) 1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion IC-GREEN is indicated for fluorescence imaging of vessels (micro- and macro- vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures in adults and pediatric patients aged 1 month and older. 1.2 Visualization of Extrahepatic Biliary Ducts IC-GREEN is indicated for fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older . 1.3 Lymphatic Mapping of Cervical and Uterine Cancer IC-GREEN is indicated for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer for which this procedure is a component of intraoperative management . 1.4 Ophthalmic Angiography IC-GREEN is indicated for use in ophthalmic angiography in adults and pediatric patients."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Hypersensitivity Reactions Advise patients to seek medical attention for reactions following injection of IC-GREEN such as difficulty breathing, swollen tongue or throat, skin reactions including hives, itching and flushed or pale skin, low blood pressure, a weak and rapid pulse and other symptoms or signs of an anaphylactic reaction [see Warnings and Precautions ( 5.1 )] ."],"mechanism_of_action":["12.1 Mechanism of Action When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor. These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and macro-vasculature, blood flow and tissue perfusion, the extrahepatic biliary ducts, and for lymphatic mapping of lymph nodes and lymphatic vessels."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been performed to evaluate the potential for carcinogenicity, mutagenicity, or impairment of fertility by indocyanine green."],"openfda":{"application_number":["NDA011525"],"brand_name":["IC-Green"],"generic_name":["INDOCYANINE GREEN"],"is_original_packager":[true],"manufacturer_name":["Renew Pharmaceuticals Limited"],"package_ndc":["70100-825-02","70100-725-01","0409-4887-17","70100-810-02","70100-710-01"],"product_ndc":["70100-810","70100-825"],"product_type":["HUMAN PRESCRIPTION DRUG"],"spl_id":["bb82db71-b087-4274-bd9c-cb388d7dbaeb"],"spl_set_id":["ccd92843-1f0a-4ece-9978-4b300d158886"]},"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL – 10mg Vial 10mg Vial Label NDC 70100-710-01 Rx only Sterile IC-GREEN ® (indocyanine green for injection) 10 mg/Vial Single-Patient-Use For Intravenous or Interstitial Use After reconstitution, use within 6 hours. Discard unused portion. Distributed by: Diagnostic Green LLC 51141 12/2025 Principal Display Panel - 10mg Vial","PRINCIPAL DISPLAY PANEL – 10mg Carton 10mg Carton Label NDC 70100-810-02 Rx Only - Sterile IC-GREEN ® (indocyanine green for injection) 10 mg/Vial Single-Patient-Use For Intravenous or Interstitial Use Distributed by: Diagnostic Green LLC Back Panel NDC 70100-810-02 Rx Only - Sterile Recommended Dosage and Reconstitution Instructions: See Prescribing Information Use within 6 hours after reconsituition. STORAGE: Store at 20° to 25° C (68° to 77°F) KIT CONTAINS: • Six vials of IC-GREEN (10 mg each) • Six Sterile Water for Injection (10 mL each) IC-GREEN ® (indocyanine green for injection) 10 mg/Vial Single-Patient-Use For Intravenous or Interstitial Use Side Panel IC-GREEN ® (indocyanine green for injection) Distributed by: Diagnostic Green LLC Farmington Hills MI 48331 USA Manufactured by: Lyocontract GmbH 38871 Ilsenburg GERMANY Sterile Water Manufactured by: Hospira, Inc. Rocky Mount, NC 27804 or Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 12/2025 Principal Display Panel - 10mg Carton","PRINCIPAL DISPLAY PANEL – 25mg Vial 25mg Vial Label NDC 70100-725-01 Rx only Sterile IC-GREEN ® (indocyanine green for injection) 25 mg/Vial Single-Patient-Use For Intravenous or Interstitial Use After reconstitution, use within 6 hours. Discard unused portion. Discard after ___/___/___ Time ___:___ Distributed by: Diagnostic Green LLC Principal Display Panel - 25mg Vial","PRINCIPAL DISPLAY PANEL – 25mg Carton 25mg Carton Label NDC 70100-825-02 Rx Only - Sterile IC-GREEN ® (indocyanine green for injection) 25 mg/Vial Single-Patient-Use For Intravenous or Interstitial Use Distributed by: Diagnostic Green LLC Back Panel NDC 70100-825-02 Rx Only - Sterile Recommended Dosage and Reconstitution Instructions: See Prescribing Information Use within 6 hours after reconsituition. STORAGE: Store at 20° to 25° C (68° to 77°F) KIT CONTAINS: • Six vials of IC-GREEN (25 mg each) • Six Sterile Water for Injection (10 mL each) IC-GREEN ® (indocyanine green for injection) 25 mg/Vial Single-Patient-Use For Intravenous or Interstitial Use Side Panel IC-GREEN ® (indocyanine green for injection) Distributed by: Diagnostic Green LLC Farmington Hills MI 48331 USA Manufactured by: Patheon Italia S.p.A. 20052 Monza (Milano) ITALY or Lyocontract GmbH 38871 Ilsenburg GERMANY Sterile Water Manufactured by: Hospira, Inc. Rocky Mount, NC 27804 or Fresenius Kabi USA, LLC Grand Island, NY 14072 or Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 04/2025 Principal Display Panel - 25mg Carton","PRINCIPAL DISPLAY PANEL – Sterile Water Vial Sterile Water Label 10 mL Single-dose Sterile Water for Injection, USP FOR DRUG DILUENT USE Rx only NDC 0409-4887-17 Contains no antimicrobial or other added substance. Sterile, nonpyrogenic. Do not give intravenously unless rendered nearly isotonic. Hospira, Inc. RL-4428 Lake Forest, IL 60045 USA Principal Display Panel - Sterile Water Vial"],"pediatric_use":["8.4 Pediatric Use Use of IC-GREEN for visualization of vessels, blood flow and tissue perfusion has been established in pediatric patients aged 1 month and older. Pediatric use is supported by published data in 49 pediatric patients who received indocyanine green for assessment of blood flow and tissue perfusion in cardiovascular, vascular, and plastic, micro- and reconstructive surgical procedures, and by clinical trials in adults. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults [see Dosage and Administration ( 2.1 )] . The use of IC-GREEN for visualization of vessels, blood flow and tissue perfusion has not been established in pediatric patients aged less than 1 month. Use of IC-GREEN for visualization of extrahepatic biliary ducts has been established in pediatric patients aged 12 years and older. Pediatric use is supported by clinical trials in adults in addition to clinical use in pediatric patients. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults [see Dosage and Administration ( 2.2 )] . The use of IC-GREEN for visualization of extrahepatic biliary ducts has not been established in pediatric patients aged less than 12 years. Use of IC-GREEN for visualization of lymph nodes and lymphatic vessels during lymphatic mapping for cervical and uterine cancer have not been established in pediatric patients. Use of IC-GREEN for ophthalmic angiography has been established in pediatric patients. Pediatric use is supported by evidence from the published literature."],"pharmacodynamics":["12.2 Pharmacodynamics There are no pharmacodynamic data."],"pharmacokinetics":["12.3 Pharmacokinetics Distribution Following intravenous injection, indocyanine green binds to plasma proteins (98%) and is largely confined to the intravascular compartment. Indocyanine green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin. Following interstitial injection, indocyanine green binds to proteins in lymph fluid and the interstitial space, is taken up by the lymphatic vessels, and drains to the lymph nodes. Since excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature, IC-GREEN is useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera. Elimination Indocyanine green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile."],"pregnancy":["8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of IC-GREEN in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."],"recent_major_changes":["Indications and Usage, For determining Cardiac Output, Hepatic Function, and Liver Blood Flow (1.1) Removed 12/2024 Indications and Usage ( 1.1 , 1.2 , 1.3 ) 12/2024 Dosage and Administration, Indicator-Dilution Studies and Hepatic Function Studies (2.1, 2.2) Removed 12/2024 Dosage and Administration ( 2.1 , 2.2 , 2.3 , 2.5 ) 12/2024 Dosage and Administration ( 2.5 ) 01/2026"],"risks":["Risk Summary There are no adequate and well-controlled studies of IC-GREEN in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.","Risk Summary Seventeen cases of indocyanine green use in lactating women have been reported in the scientific literature with no adverse events observed in the breastfed infant. However, there are no data on the presence of indocyanine green in human milk or the effects on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for IC-GREEN and any potential adverse effects on the breastfed infant from IC-GREEN or from the underlying maternal condition."],"set_id":"ccd92843-1f0a-4ece-9978-4b300d158886","spl_product_data_elements":["IC-Green Indocyanine Green IC-Green Indocyanine Green INDOCYANINE GREEN INDOCYANINE GREEN ACID FORM WATER NITROGEN Sterile Water Water WATER WATER IC-Green Indocyanine Green IC-Green Indocyanine Green INDOCYANINE GREEN INDOCYANINE GREEN ACID FORM WATER NITROGEN Sterile Water Water WATER WATER"],"spl_unclassified_section":["10 mg/vial Manufactured by: LYOCONTRACT GmbH 38871 Ilsenburg, GERMANY Sterile Water for Injection, USP is manufactured by: Hospira, Inc. Rocky Mount, NC 27804 or Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 25 mg/vial Manufactured by: Patheon Italia S.p.A. 20900 Monza (MB), ITALY or LYOCONTRACT GmbH 38871 Ilsenburg, GERMANY Sterile Water for Injection, USP is manufactured by: Fresenius Kabi USA, LLC Grand Island, NY 14072 or Hospira, Inc. Rocky Mount, NC 27804 or Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 Distributed by: Diagnostic Green LLC Farmington Hills, MI 48331 51047"],"spl_unclassified_section_table":["
10 mg/vialManufactured by: LYOCONTRACT GmbH 38871 Ilsenburg, GERMANY Sterile Water for Injection, USP is manufactured by: Hospira, Inc. Rocky Mount, NC 27804orHikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 0792225 mg/vialManufactured by: Patheon Italia S.p.A. 20900 Monza (MB), ITALYorLYOCONTRACT GmbH 38871 Ilsenburg, GERMANYSterile Water for Injection, USP is manufactured by: Fresenius Kabi USA, LLC Grand Island, NY 14072orHospira, Inc. Rocky Mount, NC 27804orHikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of IC-GREEN in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 Lactation Risk Summary Seventeen cases of indocyanine green use in lactating women have been reported in the scientific literature with no adverse events observed in the breastfed infant. However, there are no data on the presence of indocyanine green in human milk or the effects on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for IC-GREEN and any potential adverse effects on the breastfed infant from IC-GREEN or from the underlying maternal condition. 8.4 Pediatric Use Use of IC-GREEN for visualization of vessels, blood flow and tissue perfusion has been established in pediatric patients aged 1 month and older. Pediatric use is supported by published data in 49 pediatric patients who received indocyanine green for assessment of blood flow and tissue perfusion in cardiovascular, vascular, and plastic, micro- and reconstructive surgical procedures, and by clinical trials in adults. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults [see Dosage and Administration ( 2.1 )] . The use of IC-GREEN for visualization of vessels, blood flow and tissue perfusion has not been established in pediatric patients aged less than 1 month. Use of IC-GREEN for visualization of extrahepatic biliary ducts has been established in pediatric patients aged 12 years and older. Pediatric use is supported by clinical trials in adults in addition to clinical use in pediatric patients. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults [see Dosage and Administration ( 2.2 )] . The use of IC-GREEN for visualization of extrahepatic biliary ducts has not been established in pediatric patients aged less than 12 years. Use of IC-GREEN for visualization of lymph nodes and lymphatic vessels during lymphatic mapping for cervical and uterine cancer have not been established in pediatric patients. Use of IC-GREEN for ophthalmic angiography has been established in pediatric patients. Pediatric use is supported by evidence from the published literature. 8.5 Geriatric Use Of the total number of patients in clinical studies of indocyanine green for injection for visualization of vessels, blood flow and tissue perfusion, 7% were 65 and over, while 1% were 75 and over. Of the total number of patients in clinical studies of indocyanine green for injection for visualization of lymph nodes and lymphatic vessels during lymphatic mapping of cervical and uterine cancer, 9% were 65 and over, while 2% were 75 and over. Clinical studies of indocyanine green for injection for visualization of extrahepatic biliary ducts did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy."],"version":"4","warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: Hypersensitivity reactions including anaphylaxis and urticaria have occurred. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor patients. ( 5.1 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions including anaphylaxis, urticaria and deaths due to anaphylaxis have been reported following intravenous administration of IC-GREEN [see Adverse Reactions ( 6 )] . IC-GREEN is contraindicated in patients with a history of hypersensitivity to indocyanine green [see Contraindications ( 4 )] . Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions. 5.2 Interference with Thyroid Radioactive Iodine Uptake Studies Because IC-GREEN contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration [see Drug Interactions ( 7 )] ."]}